JP7333269B2 - 術後悪心嘔吐の救援治療 - Google Patents

術後悪心嘔吐の救援治療 Download PDF

Info

Publication number
JP7333269B2
JP7333269B2 JP2019543311A JP2019543311A JP7333269B2 JP 7333269 B2 JP7333269 B2 JP 7333269B2 JP 2019543311 A JP2019543311 A JP 2019543311A JP 2019543311 A JP2019543311 A JP 2019543311A JP 7333269 B2 JP7333269 B2 JP 7333269B2
Authority
JP
Japan
Prior art keywords
amisulpride
ponv
vomiting
administered
nausea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019543311A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020506209A (ja
JPWO2018146490A5 (enExample
JP2020506209A5 (enExample
Inventor
クライブ ギルバート，ジュリアン
ウィリアム グリストウッド，ロバート
フォックス，ガブリエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acacia Pharma Ltd
Original Assignee
Acacia Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acacia Pharma Ltd filed Critical Acacia Pharma Ltd
Publication of JP2020506209A publication Critical patent/JP2020506209A/ja
Publication of JP2020506209A5 publication Critical patent/JP2020506209A5/ja
Publication of JPWO2018146490A5 publication Critical patent/JPWO2018146490A5/ja
Priority to JP2022196161A priority Critical patent/JP7526244B2/ja
Application granted granted Critical
Publication of JP7333269B2 publication Critical patent/JP7333269B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019543311A 2017-02-10 2018-02-09 術後悪心嘔吐の救援治療 Active JP7333269B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022196161A JP7526244B2 (ja) 2017-02-10 2022-12-08 術後悪心嘔吐の救援治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1702250.0A GB201702250D0 (en) 2017-02-10 2017-02-10 Method
GB1702250.0 2017-02-10
PCT/GB2018/050374 WO2018146490A1 (en) 2017-02-10 2018-02-09 Rescue treatment of post operative nausea and vomiting

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022196161A Division JP7526244B2 (ja) 2017-02-10 2022-12-08 術後悪心嘔吐の救援治療

Publications (4)

Publication Number Publication Date
JP2020506209A JP2020506209A (ja) 2020-02-27
JP2020506209A5 JP2020506209A5 (enExample) 2021-03-18
JPWO2018146490A5 JPWO2018146490A5 (enExample) 2022-06-14
JP7333269B2 true JP7333269B2 (ja) 2023-08-24

Family

ID=58462198

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019543311A Active JP7333269B2 (ja) 2017-02-10 2018-02-09 術後悪心嘔吐の救援治療
JP2022196161A Active JP7526244B2 (ja) 2017-02-10 2022-12-08 術後悪心嘔吐の救援治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022196161A Active JP7526244B2 (ja) 2017-02-10 2022-12-08 術後悪心嘔吐の救援治療

Country Status (14)

Country Link
US (4) US11357753B2 (enExample)
EP (1) EP3579831A1 (enExample)
JP (2) JP7333269B2 (enExample)
KR (2) KR20190111993A (enExample)
CN (1) CN110603036A (enExample)
AU (2) AU2018218310B2 (enExample)
BR (1) BR112019016565A2 (enExample)
CA (1) CA3052535A1 (enExample)
EA (1) EA201991667A1 (enExample)
GB (1) GB201702250D0 (enExample)
IL (2) IL298486B2 (enExample)
MX (1) MX388736B (enExample)
WO (1) WO2018146490A1 (enExample)
ZA (1) ZA201905212B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201702250D0 (en) * 2017-02-10 2017-03-29 Acacia Pharma Ltd Method
IT201900013524A1 (it) * 2019-07-31 2021-01-31 Laboratori Baldacci Spa Nuove formulazioni di amisulpride
WO2022008901A1 (en) * 2020-07-06 2022-01-13 Acacia Pharma Ltd Therapy of post-operative nausea and vomiting

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1004020A (en) 1964-04-24 1965-09-08 Standard Telephones Cables Ltd Improvements in or relating to the mounting of electrical components
FR2415099A1 (fr) 1978-01-20 1979-08-17 Ile De France Nouveaux derives de 4-amino-5-alkylsulfonyl ortho-anisamides, leurs procedes de preparation et leur application comme psychotropes
GB9305593D0 (en) 1993-03-18 1993-05-05 Smithkline Beecham Plc Pharmaceuticals
US6169094B1 (en) 1998-07-14 2001-01-02 Sanofi-Synthelabo Compositions of (S) (-)-amisulpride
DE10163421A1 (de) 2001-12-21 2003-07-31 Gruenenthal Gmbh Verwendung von (+)-(1S,2S)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol als Antiemetikum
MY143789A (en) 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting
DE102005013726A1 (de) 2005-03-22 2006-09-28 Grünenthal GmbH Transdermale therapeutische Systeme mit verbesserter Verträglichkeit
GB0506800D0 (en) 2005-04-04 2005-05-11 Merck Sharp & Dohme New uses
WO2007067714A2 (en) 2005-12-08 2007-06-14 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
AU2007211091B8 (en) 2006-01-27 2013-08-29 Adare Pharmaceuticals, Inc. Drug delivery systems comprising weakly basic selective serotonin 5-HT3 blocking agent and organic acids
EP1988883A1 (fr) 2006-02-17 2008-11-12 Trimaran Limited Nouvelles compositions pharmaceutiques destinees a optimiser des traitements de substitution et elargir la pharmacopee au traitement global des addictions
US7825156B2 (en) 2007-02-02 2010-11-02 Copharms Method of treating bipolar depression with a benzamide derivative
EP2240022B1 (en) 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Bilayered tablets comprising oxycodone and promethazine
US8138169B2 (en) 2008-04-11 2012-03-20 Comgenrx, Inc. Combination therapy for bipolar disorder
US20110003005A1 (en) 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
RS53491B1 (sr) 2009-11-18 2015-02-27 Helsinn Healthcare Sa Kompozicije za lečenje centralno posredovane mučnine i povraćanja
GB201004020D0 (en) 2010-03-11 2010-04-21 Acacia Pharma Ltd New therapeutic use
MX353209B (es) 2010-06-18 2018-01-08 Altos Therapeutics Llc Antagonistas d2, metodos de sintesis y metodos de uso.
WO2015054429A1 (en) 2013-10-08 2015-04-16 Innopharma, Inc Aprepitant oral liquid formulations
GB201506116D0 (en) * 2015-04-10 2015-05-27 Acacia Pharma Ltd Kit and combination therapy for nausea and vomiting
GB201618425D0 (en) 2016-11-01 2016-12-14 Acacia Pharma Ltd method
GB201702250D0 (en) * 2017-02-10 2017-03-29 Acacia Pharma Ltd Method

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Ａｒｃｈｉｖｅ ｏｆ Ｈｉｓｔｏｒｙ ｆｏｒ ＮＣＴ０２６４６５６６，２０１７年０１月２３日，ＵＲＬは以下：［ｈｔｔｐｓ：／／ｃｌｉｎｉｃａｌｔｒｉａｌｓ．ｇｏｖ／ｃｔ２／ｈｉｓｔｏｒｙ／ＮＣＴ０２６４６５６６？Ｖ＿４＝Ｖｉｅｗ］
Ｂｒ． Ｊ． Ａｎｅａｓｔｈ．，２０１３年，Ｖｏｌ．１１１ Ｎｏ．６，ｐｐ．９３８－９４５
ＲＮ： ７１６７５－８５－９，ＤＡＴＡＢＡＳＥ ＲＥＧＩＳＴＲＹ ｏｎ ＳＴＮ，１９８４年
ＲＮ： ７１６７５－９０－６，ＤＡＴＡＢＡＳＥ ＲＥＧＩＳＴＲＹ ｏｎ ＳＴＮ，１９８４年
ＲＮ： ７１６７５－９２－８，ＤＡＴＡＢＡＳＥ ＲＥＧＩＳＴＲＹ ｏｎ ＳＴＮ，１９８４年

Also Published As

Publication number Publication date
US20200038369A1 (en) 2020-02-06
US20250367211A1 (en) 2025-12-04
EA201991667A1 (ru) 2020-02-11
US20240285579A1 (en) 2024-08-29
IL268591B (en) 2022-12-01
IL298486A (en) 2023-01-01
ZA201905212B (en) 2023-12-20
MX388736B (es) 2025-03-20
US20230100786A1 (en) 2023-03-30
JP2020506209A (ja) 2020-02-27
AU2024203155B2 (en) 2025-03-13
CN110603036A (zh) 2019-12-20
IL268591B2 (en) 2023-04-01
IL298486B1 (en) 2024-05-01
IL298486B2 (en) 2024-09-01
AU2018218310A1 (en) 2019-08-22
NZ756051A (en) 2024-04-26
US11357753B2 (en) 2022-06-14
CA3052535A1 (en) 2018-08-16
US12005042B2 (en) 2024-06-11
AU2018218310B2 (en) 2024-02-15
KR20190111993A (ko) 2019-10-02
EP3579831A1 (en) 2019-12-18
KR20240001288A (ko) 2024-01-03
WO2018146490A1 (en) 2018-08-16
BR112019016565A2 (pt) 2020-03-31
JP2023027213A (ja) 2023-03-01
AU2024203155A1 (en) 2024-05-30
IL268591A (en) 2019-09-26
JP7526244B2 (ja) 2024-07-31
GB201702250D0 (en) 2017-03-29
US12329740B2 (en) 2025-06-17

Similar Documents

Publication Publication Date Title
JP7526244B2 (ja) 術後悪心嘔吐の救援治療
CN107872975A (zh) 用于治疗恶心和呕吐的氨磺必利和其它止吐药的组合
JP2023058654A (ja) アミスルプリドによる術後嘔吐の治療法
US20230263770A1 (en) Therapy of post-operative nausea and vomiting
JPWO2018146490A5 (enExample)
HK40013552A (en) Rescue treatment of post operative nausea and vomiting
NZ796242A (en) Rescue treatment of post operative nausea and vomiting
EA042759B1 (ru) Экстренное лечение постоперационной тошноты и рвоты
HK40091212A (zh) 术後恶心和呕吐的疗法
EA048577B1 (ru) Терапия послеоперационной тошноты и рвоты
HK40005558A (en) Therapy of post-operative emesis with amisulpride

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210203

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220413

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20220606

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221208

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221208

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20221221

C876 Explanation why request for accelerated appeal examination is justified

Free format text: JAPANESE INTERMEDIATE CODE: C876

Effective date: 20230116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230113

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230131

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230201

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230303

C305 Report on accelerated appeal examination

Free format text: JAPANESE INTERMEDIATE CODE: C305

Effective date: 20230307

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20230315

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20230315

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20230329

C302 Record of communication

Free format text: JAPANESE INTERMEDIATE CODE: C302

Effective date: 20230414

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230526

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230814

R150 Certificate of patent or registration of utility model

Ref document number: 7333269

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150